Chimeric Therapeutics Ltd (ASX: CHM) Share Price and News

Mr Hains has over 30 years of experience in roles with a portfolio of ASX and NASDAQ listed companies.

Dr Russell is a haematologist/oncologist and has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both FDA and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. She is a member of the Risk committee.

Mr Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Since September 2023 Mr Sullivan has been the CFO of Convergent Therapeutics, Inc. He is the chairperson of Risk Committee.

Prof Prince is a professor of Medicine at both Melbourne and Monash Universities. He holds the position of Professor and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and serves as a Haematologist at the Peter MacCallum Cancer Centre. In addition to his clinical and research roles, Professor Prince is involved in philanthropy and healthcare advocacy. He is a founding member of the Snowdome Foundation. He also serves on the Australian Blood Cancer Taskforce.

Dr Glover is an executive with over 20 years of leadership experience across global biopharmaceuticals, cell therapy, biomaterials, and life sciences, spanning both public and private companies. Dr Glover brings expertise in cell and gene therapy, corporate development, and capital formation, with a record of executing value-creating strategic transactions, while leading organisations through critical clinical, operational and commercial inflection points. Dr Glover has held senior leadership roles at Imugene, Celularity, Kite Pharma, Genentech, Roche, and Illumina, with responsibilities spanning corporate strategy, corporate development, manufacturing expansion, supply chain, and commercial launch execution. Dr Glover also serves on several other boards including Lamorinda Therapeutics and Basilard BioTech.

-

-

-